 |
|
| Blog results | Results 1 - 10 of about 463 for taxotere ovarian cancer. (0.23 seconds) |
| Sorted by relevance Sort by date |
| 15 Sep 2009 by Paul Cacciatore Related Articles [Therapeutic effect of docetaxel combined with oxaliplatin for treatment of recurrent epithelial ovarian cancer.] Nan Fang Yi Ke Da Xue Xue Bao. 2009 Nov 20;29(11):2319-2320 Authors: Wang J, Han N, Wang HL, Zhang ZM, Fan QX OBJECTIVE: To evaluate the efficacy and safety of docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) for treatment of rec […] ABC transporter gene expression in benign and malignant ovarian tissue. November 20, 2009 ... Libby's H*O*P*E* (*Helping *Ovarian Cancer... - http://healthinfoispower.wordpress.com/ - References [ More results from Libby's H*O*P*E* (*Helping *Ovarian Cancer... ] |
| 6 Feb 2008 by M L the response rate of patients with ovarian cancer who have failed paraplatin® and paclitaxel and were treated with taxotere® has been determined in a gynecologic oncology group (gog) clinical trial. the results of this clinical trial ... Cancer Treatment - http://cancertreatments.typepad.com/cancer_treatment/ [ More results from Cancer Treatment ] |
| 27 Oct 2009 by Jyotsna Ramani Taxotere which is chemically better known as docetaxel is a clinically well-established anti-mitotic chemotherapy medication used for the treatment of breast, ovarian and non-small cell lung cancer. The drug has an approved claim for ... FavStocks - http://www.favstocks.com/ |
| 27 Feb 2007 by Kristina Collins Some academic oncology groups had as their major ovarian cancer project, clinical trials to show that Taxotere (Docetaxel) could be the new "standard" therapy. Patients were treated with Taxol + Carboplatin. ... The Cancer Blog - http://www.thecancerblog.com/ - References [ More results from The Cancer Blog ] |
| 7 Sep 2009 by Sean The deal would give J&J a potential blockbuster in prostate cancer to market alongside its portfolio oncologics Velcade (for myeloma) and Yondelis (ovarian cancer) company. With the Algeta deal, Bayer will also get a ... The deal will allow Algeta to bring the drug through Phase III and to launch Phase II studies of Alpharadin in combination with Taxotere for hormone resistant prostate cancer bone metastases and in breast cancer. "Our goal is to make Alpharadin the first ... EuroPharma Today - http://www.europharmatoday.com/ - References |
| 20 Dec 2006 by rbailey@reason.com (Ronald Bailey) Now that Taxol went off patent, some academic oncology groups have (as their major ovarian cancer project) clinical trials to show that Platinum/Docetaxel (a drug like Taxol, but still on patent) can now be the new "standard" therapy. ... If Taxol/Carboplatin doesn't work, they'll be crossed over to Docetaxel (Taxotere), a drug which is mostly (if not completely) cross resistant with Taxol, for which the cancer clinic will collect several thousand dollars from the large ... Reason Magazine - Hit & Run - http://www.reason.com/blog - References |
| 11 Feb 2007 Docetaxel is an anti-neoplastic medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel is marketed under the name Taxotere Injection Concentrate by Sanofi-Aventis. ... Latest News from 3Dchem.com - http://www.3dchem.com/ |
| 15 Oct 2009 by aftercancer@yahoo.com (Kate Burton) Taxotere is derived from the European yew tree and is used in breast, non small cell lung and ovarian cancer treatment. The Madagascar periwinkle is the source of at least four drugs; Vincristine used for treatment of non Hodgkin's, ... After cancer, now what - http://www.aftercancernowwhat.com/ |
| 11 Aug 2007 by Ferrandina, G, Ludovisi, M, De Vincenzo,... Background: A prospective phase II study was conducted to evaluate the efficacy and toxicity of the combination docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) in ovarian cancer patients recurring after a platinum-free interval (PFI) ... Annals of Oncology - recent issues - http://annonc.oxfordjournals.org/ |
| 21 Oct 2009 by AP Peregrine said the data compares favorably with separate and prior published study showing Taxotere alone prompted a 41 percent response rate in advanced breast cancer patients. Since the two studies are separate and ... October 7th, 2009 WASHINGTON - A research team led by Indian origin scientist has developed a drug to "seek and destroy" common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers. Principle investigator Dr. ... Health News - http://blog.taragana.com/health/ |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
